Greenland Mines (NASDAQ: GRML) is sharpening its focus on critical minerals with a series of strategic moves, including the planned spin-off of its biotechnology division in the fourth quarter of 2026. The company, which has been transitioning into a dedicated rare earths and critical minerals player, also announced that Nasdaq has formally approved its application related to the March 2026 transaction, resolving prior deficiencies and bringing the company into full compliance with listing requirements.
The spin-off will allow Greenland Mines to concentrate on its mining assets, particularly the Sarfartoq neodymium-praseodymium (NdPr) rare earths project in southwest Greenland. The acquisition of Sarfartoq was completed on Sept. 1 following approval by the Government of Greenland. An independent S-K 1300 Initial Assessment for the ST1 deposit estimated a high-case pre-tax net present value of approximately $2.05 billion and a pre-tax internal rate of return of 118.6%. According to the company, planned annual NdPr oxide production from ST1 would equal approximately 34% of current NdPr oxide refining outside China based on 2025 consumption levels during each of the project's nine scheduled operating years.
This move comes at a time when global demand for rare earth elements, particularly NdPr, is surging due to their use in permanent magnets for electric vehicles, wind turbines, and other clean energy technologies. With China dominating the rare earth supply chain, Greenland Mines' progress on Sarfartoq could offer a significant non-Chinese source of these critical materials. The company's Skaergaard palladium-gold-platinum project in southeast Greenland adds further diversification to its portfolio.
In conjunction with these operational advancements, Greenland Mines is reshaping its board of directors. Riad El-Dada and Dr. Shalom Hirschman are stepping down, and capital markets veteran Jason Hawkins is joining the board. This change is expected to bring additional expertise as the company advances Sarfartoq and its Skaergaard project. The company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals, and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
The biotech division, which includes Klotho’s KLTO-202 primary indication for ALS, will be spun off to shareholders, allowing each entity to focus on its respective core business. This separation is anticipated to unlock value for shareholders by enabling clearer investment mandates and more efficient capital allocation. The spin-off is subject to customary conditions and approvals.
Greenland Mines' achievements mark a pivotal step in its transformation, positioning the company to play a crucial role in the global critical minerals supply chain. With the Sarfartoq project's robust economics and the company's renewed corporate governance, Greenland Mines is well-placed to capitalize on the growing demand for rare earth elements. For more information on the company's progress, visit the full press release at https://ibn.fm/QN1U9.
